| 1 |
Bigot P, Barthelemy P, Boissier R, Khene Z, Pettenati C, Bernhard J, Correas J, Doumerc N, Gimel P, Ingels A, Nouhaud F, Ouzaïd I, Rioux-leclercq N, Albiges L, Rouprêt M. French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer. Progrès en Urologie 2022;32:1195-1274. [DOI: 10.1016/j.purol.2022.07.146] [Reference Citation Analysis]
|
| 2 |
Wang K, Liu Z, Hong P, Qin Y, Zhao X, Zhang H, Liu C, Ge L, Ma L. T.H.R.O.B.V.S. Score – A Comprehensive Model to Predict the Surgical Complexity of Renal Cell Carcinoma With Tumor Thrombus. Front Oncol 2022;12:900550. [DOI: 10.3389/fonc.2022.900550] [Reference Citation Analysis]
|
| 3 |
Laru L, Ronkainen H, Ohtonen P, Vaarala MH. Nephrectomy improves the survival of metastatic renal cell cancer patients with moderate to good performance status-results from a Finnish nation-wide population-based study from 2005 to 2010. World J Surg Oncol 2021;19:190. [PMID: 34183025 DOI: 10.1186/s12957-021-02308-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 4 |
Elkassem AA, Allen BC, Sharbidre KG, Rais-Bahrami S, Smith AD. Update on the Role of Imaging in Clinical Staging and Restaging of Renal Cell Carcinoma Based on the AJCC 8th Edition, From the AJR Special Series on Cancer Staging. AJR Am J Roentgenol 2021;217:541-55. [PMID: 33759558 DOI: 10.2214/AJR.21.25493] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 5 |
Bensalah K, Bigot P, Albiges L, Bernhard J, Bodin T, Boissier R, Correas J, Gimel P, Hetet J, Long J, Nouhaud F, Ouzaïd I, Rioux-leclercq N, Méjean A. Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2020–2022 : prise en charge du cancer du rein. Progrès en Urologie 2020;30:S2-S51. [DOI: 10.1016/s1166-7087(20)30749-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 6 |
Becher E, Jericevic D, Huang WC. Minimally Invasive Surgery for Patients with Locally Advanced and/or Metastatic Renal Cell Carcinoma. Urol Clin North Am 2020;47:389-97. [PMID: 32600540 DOI: 10.1016/j.ucl.2020.04.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 7 |
Oake JD, Patel P, Lavallée LT, Lattouf JB, Saarela O, Klotz L, Moore RB, Kapoor A, Finelli A, Rendon RA, Kawakami J, So AI, Drachenberg DE. Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database. Can Urol Assoc J 2020;14:24-30. [PMID: 31348746 DOI: 10.5489/cuaj.5941] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 8 |
Damodaran S, Abel EJ. Pre-surgical Treatment of Renal Cell Carcinoma. Diagnosis and Surgical Management of Renal Tumors 2019. [DOI: 10.1007/978-3-319-92309-3_14] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 9 |
Bhindi B, Leibovich BC. Approach to the Management of Large and Advanced Renal Tumors. Diagnosis and Surgical Management of Renal Tumors 2019. [DOI: 10.1007/978-3-319-92309-3_9] [Reference Citation Analysis]
|
| 10 |
Bensalah K, Albiges L, Bernhard J, Bigot P, Bodin T, Boissier R, Correas J, Gimel P, Hetet J, Long J, Nouhaud F, Ouzaïd I, Rioux-leclercq N, Méjean A. Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : prise en charge du cancer du rein. Progrès en Urologie 2018;28:R5-R33. [DOI: 10.1016/j.purol.2019.01.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 11 |
Bensalah K, Albiges L, Bernhard JC, Bigot P, Bodin T, Boissier R, Correas JM, Gimel P, Hetet JF, Long JA, Nouhaud FX, Ouzaïd I, Rioux-Leclercq N, Méjean A. RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : prise en charge du cancer du reinFrench ccAFU guidelines – Update 2018–2020: Management of kidney cancer. Prog Urol 2018;28:S3-S31. [PMID: 30473002 DOI: 10.1016/j.purol.2018.09.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 12 |
Kassouf W, Monteiro LL, Drachenberg DE, Fairey AS, Finelli A, Kapoor A, Lattouf JB, Leveridge MJ, Power NE, Pouliot F, Rendon RA, Sabbagh R, So AI, Tanguay S, Breau RH. Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma. Can Urol Assoc J 2018;12:231-8. [PMID: 30139427 DOI: 10.5489/cuaj.5462] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
